Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGFR1/2 peptide vaccine study in recurrent or refractory brain tumors
jRCTs031180162Phase 2Recruiting
- Start
- Feb 2018
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VEGFR1 peptide vaccine and incomplete freund's adjuvant in brain neoplasm, hemangiopericytoma (HPC), Haemangioblastoma and 3 more. Primary endpoint: Safety and clinical efficacy of vaccine therapy using VEGFR1 and VEGFR2 peptide. Started Feb 2018; status: recruiting.
02
Drugs
VEGFR1 peptide vaccineincomplete freund's adjuvant
03
Conditions
brain neoplasmhemangiopericytoma (HPC)Haemangioblastomameningiomachordoma
Beyond the preview
Go deeper on jRCTs031180162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180162.